Johnson & Johnson Talcum Powder Products
The Johnson & Johnson talcum powder MDL, centralized in the District of New Jersey in 2016, consolidates claims that long-term use of talc-based body powder products caused ovarian cancer and, in a related claim track, mesothelioma. With 69,250 actions coordinated, it is one of the largest personal-injury dockets in the current federal MDL system, reflecting both the products' decades of widespread consumer use and a large, wide-ranging causation and corporate-knowledge dispute over what Johnson & Johnson knew about potential asbestos contamination and cancer risk.
What makes this docket structurally distinctive, and central to understanding its duration and resolution risk, is that Johnson & Johnson has pursued resolution primarily through a subsidiary bankruptcy strategy rather than the ordinary civil settlement process available in most mass torts. Bankruptcy courts have repeatedly rejected that approach: a 2023 proposal built around a roughly $9 billion settlement covering an estimated 50,000 claimants was blocked on the grounds that the subsidiary was not in the financial distress bankruptcy law requires, leaving a very large claim population, at least 38,000 lawsuits at that point, active outside the bankruptcy proceeding.
That bankruptcy overhang, rather than any single bellwether trial or settlement-fund timeline, is the dominant driver of duration and resolution risk in this docket right now. Because the corporate strategy for resolving the bulk of the claims has repeatedly changed forum and structure, the more reliable analytical approach is tracking which forum, bankruptcy or civil MDL, currently has jurisdiction over which claim population, rather than projecting a single settlement outcome or timeline for the docket as a whole.
Criterica Intelligence's platform is built to track exactly this kind of forum-contingent structural complexity, reading a docket like this one for its current procedural reality rather than assuming a single, settled resolution path.
In 2023, Johnson & Johnson proposed a global settlement of roughly $9 billion covering an estimated 50,000 claimants through its subsidiary's bankruptcy proceeding; bankruptcy judges blocked that plan on the grounds that the subsidiary was not in financial distress, and at least 38,000 lawsuits reportedly remained pending outside the bankruptcy attempt at that time.
Talc-based body powders saw decades of widespread consumer use, and the litigation covers two related but distinct injury theories, ovarian cancer and mesothelioma, which together generated one of the largest personal-injury claim populations in the federal MDL system.
J&J placed the talc liabilities into a subsidiary and sought to resolve them through that subsidiary's bankruptcy rather than through the civil MDL's ordinary settlement process, a strategy bankruptcy courts have repeatedly rejected, including a 2023 plan found to lack the required financial distress.
The unresolved bankruptcy strategy itself. Because the forum handling the bulk of claims has shifted more than once, tracking which forum currently has jurisdiction over which claims matters more than any single bellwether or settlement-fund timeline.
They continue through the ordinary civil MDL, meaning coordinated pretrial litigation, potential bellwether development, and eventual settlement or remand for trial, independent of whatever happens in the bankruptcy proceeding.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.